Clinical Consequences of Withdrawing Guideline-Directed Medical Therapy in Heart Failure with Improved Ejection Fraction: A Systematic Review and Meta-Analysis.

Effects of pharmacological blood pressure lowering in heart failure with mildly reduced or preserved ejection fraction: a meta-analysis.

BACKGROUND The role of blood pressure (BP) lowering in patients with heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) remains uncertain, and it is unclear to what extent the existing benefits of therapies are mediated by BP reduction. METHODS AND RESULTS A systematic review and met...

The Impact of β-Blocker Therapy on Peak VO2 in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis.

Beta-Blocker Discontinuation in Heart Failure with Preserved or Improved Ejection Fraction: A Systematic Review.

BACKGROUND Beta-blockers are commonly used among patients with heart failure and preserved or improved ejection fraction (HFpEF or HFimpEF). The benefits of beta-blockers in these populations are not clear, which may raise consideration of discontinuation. We conducted a systematic review on the effects of beta-blocker...

Clinical characteristics associated with failure to achieve a prespecified guideline-directed medical therapy target at discharge in patients with HFrEF undergoing scheduled hospitalization: a secondary analysis of the HEROES study

Guideline-directed medical therapy (GDMT) is crucial for the pharmacological management of heart failure (HF) with reduced ejection fraction (HFrEF). The aim of the study was to identify clinical characteristics associated with failure to achieve the prespecified stringent GDMT target in patients with HFrEF undergo...

Long-term efficacy and impact on rehospitalization of Qishen granules in patients with hypertension and heart failure with reduced ejection fraction: a multicenter, randomized, double-blind, placebo-controlled trial protocol

Heart failure with reduced ejection fraction (HFrEF) represents a severe manifestation or terminal stage of various cardiac diseases. Long-term hypertension frequently leads to pathological changes such as ventricular remodeling, resulting in HFrEF. Despite continuous advancements in medications targeting hypertens...

Differential Rates of Guideline-Directed Medical Therapy Modification in C-MIC and Control Patients: Results from the C-MIC II Trial.

BACKGROUND In the C-MIC II trial, C-MIC therapy improved outcomes in patients with heart failure (HF) with reduced ejection fraction (HFrEF). We evaluated whether differences in background HF medication adjustments influenced the observed benefits. METHODS Ambulatory patients with chronic non-ischemic HFrEF receiving...